Bionano Genomics, Inc. announced that it has entered into an original equipment manufacturing (OEM) partnership agreement with Diagens. Through the partnership, the companies plan to commercialize the first ever cytogenetic workflow using OGM plus AI chromosome karyotype analysis to detect pathogenic SVs associated with recurrent pregnancy loss and other significant genome variants that may impact a pregnancy or lead to developmental issues in a newborn. Diagens has received Class I registration and approval for Bionano's OGM reagents from China's NMPA and will register the Saphyr instrument with NMPA for clinical use in reproductive health.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9565 USD | -4.01% | +8.31% | -49.39% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.39% | 63.95M | |
+7.93% | 219B | |
+7.53% | 184B | |
+15.20% | 138B | |
+27.02% | 108B | |
-1.14% | 62.54B | |
+7.23% | 52.22B | |
+12.58% | 51.73B | |
+1.61% | 41.4B | |
+5.32% | 37.17B |
- Stock Market
- Equities
- BNGO Stock
- News Bionano Genomics, Inc.
- Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence